Alzheimer's, Autism, and Cognitive Impairment Stem Cell Treatment Study (ACIST)
This study will evaluate the use of autologous bone marrow-derived stem cells and near infrared light to improve cognitive impairment in Alzheimer's and related dementias and to improve behavior and socialization issues in adult autism spectrum disorder.
|Minimum Age||Maximum Age||Gender||Healthy Volunteers|
- Documented cognitive impairment or diagnosis of disease associated with cognitive impairment
- If under current medical therapy (drug or surgical treatment), must be stable on that treatment and unlikely to have reversal of the associated cognitive impairment as a result of the treatment
- Have the potential for improvement with the study treatment and be at minimal risk of any potential harm from the procedure
- Be medically stable and able to be medically cleared by primary care physician or a licensed primary care practitioner for the procedure
- Participants enrolling with cognitive impairment will have a Mini-Mental Status Examination score of 24 or less (mild, moderate, or severe dementia)
- Not able to undergo a neurological exam and evaluation to document the pathology
- Not able or willing to undergo followup neurological exams with the investigators or own neurologists
- Not able to provide informed consent (or have a designated responsible party who can provide consent)
- Not medically stable
- Procedure may pose significant risk of harm to participant's health or neurological function
- Women of childbearing potential must not be pregnant and should refrain from becoming pregnant for 3 months after
Participants will undergo intraveneous delivery of self-derived bone marrow stem cells and may also undergo near infrared light treatment or intranasal topical bone marrow stem cell treatment. Researchers will test the ability of the stem cell treatment, with or without infrared light, to positively affect the health and function of neurons and the brain.
The Healing Institute
Steven Levy, MD
MD Stem Cells
|Jeffrey Weiss, MD||Principal Investigator||The Healing Institute|
|Steven Levy, MD||Study Director||MD Stem Cells|
|Steven Levy, MDemail@example.com|
Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study
- Danielyan L, Schfer R, von Ameln-Mayerhofer A, Buadze M, Geisler J, Klopfer T, Burkhardt U, Proksch B, Verleysdonk S, Ayturan M, Buniatian GH, Gleiter CH, Frey WH 2nd. Intranasal delivery of cells to the brain. Eur J Cell Biol. 2009 Jun;88(6):315-24. doi: 10.1016/j.ejcb.2009.02.001. Epub 2009 Mar 25.
- Duncan T, Valenzuela M. Alzheimer's disease, dementia, and stem cell therapy. Stem Cell Res Ther. 2017 May 12;8(1):111. doi: 10.1186/s13287-017-0567-5. Review.
- Johnstone DM, Moro C, Stone J, Benabid AL, Mitrofanis J. Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease. Front Neurosci. 2016 Jan 11;9:500. doi: 10.3389/fnins.2015.00500. eCollection 2015. Review.
- Robbins JP, Price J. Human induced pluripotent stem cells as a research tool in Alzheimer's disease. Psychol Med. 2017 Nov;47(15):2587-2592. doi: 10.1017/S0033291717002124. Epub 2017 Aug 14. Review.
- Park SE, Lee NK, Na DL, Chang JW. Optimal mesenchymal stem cell delivery routes to enhance neurogenesis for the treatment of Alzheimer's disease: optimal MSCs delivery routes for the treatment of AD. Histol Histopathol. 2018 Jun;33(6):533-541. doi: 10.14670/HH-11-950. Epub 2017 Nov 29. Review.
- Shroff G. Human Embryonic Stem Cells in the Treatment of Autism: A Case Series. Innov Clin Neurosci. 2017 Apr 1;14(3-4):12-16. eCollection 2017 Mar-Apr.
- Chez M, Lepage C, Parise C, Dang-Chu A, Hankins A, Carroll M. Safety and Observations from a Placebo-Controlled, Crossover Study to Assess Use of Autologous Umbilical Cord Blood Stem Cells to Improve Symptoms in Children with Autism. Stem Cells Transl Med. 2018 Apr;7(4):333-341. doi: 10.1002/sctm.17-0042. Epub 2018 Feb 6.